Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Drug

Innovent Biologics’ IBI363 Shows Promising Results in Phase Ia/Ib Trial for Advanced Solid Tumors

Fineline Cube Jun 14, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Deals

Ronovo Surgical Secures Over RMB 300 Million in Series B to Globalize Surgical Robot

Fineline Cube Jun 14, 2024

Shanghai-based surgical robotics specialist, Ronovo Surgical, has reportedly raised over RMB 300 million (USD 41.3...

Company Deals Drug

Cellbri Bio Secures Nearly RMB 200 Million in Series B Financing to Boost CGT Commercialization

Fineline Cube Jun 14, 2024

Shenzhen Cellbri Bio-Innovation Technology Co., Ltd, a prominent player in China’s cell and gene therapy...

Company Deals Medical Device

Zhejiang Dian Diagnostics Partners with Quest Diagnostics to Advance Alzheimer’s Disease Blood Tests

Fineline Cube Jun 14, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics company based in China, has...

Company Drug

Apeloa Pharmaceutical Partners with Beijing Highthink for CRO Services on Semaglutide Generic

Fineline Cube Jun 14, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership...

Company Deals

GSK Partners with Ochre Bio to Access Liver Data for Hepatology Therapy Development

Fineline Cube Jun 14, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has entered into an agreement with fellow...

Company Drug

Pfizer’s Gene Therapy for Duchenne Muscular Dystrophy Misses Late-Stage Trial Endpoints

Fineline Cube Jun 14, 2024

Pfizer Inc. (NYSE: PFE) has announced that a late-stage clinical trial for its investigational gene...

Company Drug

AstraZeneca’s Farxiga Receives FDA Approval for Pediatric Type-2 Diabetes Treatment

Fineline Cube Jun 14, 2024

The US Food and Drug Administration (FDA) has granted regulatory approval to AstraZeneca (AZ; NASDAQ:...

Company Drug

Amgen’s Prolia Secures NMPA Approval for Treating Glucocorticoid-Induced Osteoporosis in High-Risk Patients

Fineline Cube Jun 14, 2024

Biopharmaceutical giant Amgen has received marketing approval from China’s National Medical Products Administration (NMPA) for...

Policy / Regulatory

NHSA Seeks Public Input on National Reimbursement Drug List Adjustments

Fineline Cube Jun 14, 2024

The National Healthcare Security Administration (NHSA) has unveiled the adjustment plan for the National Reimbursement...

Company Drug

Eli Lilly’s Baqsimi Gains NMPA Approval for Diabetes Hypoglycemia Treatment

Fineline Cube Jun 13, 2024

The National Medical Products Administration (NMPA) in China has granted approval to Eli Lilly &...

Company Deals

Chia Tai Tianqing and China Resource Medicine Commercial Holdings Join Forces for Pharmaceutical Industry Expansion

Fineline Cube Jun 13, 2024

Chia Tai Tianqing, a renowned name in the Chinese healthcare industry, has forged a strategic...

Company Drug

Boehringer Ingelheim’s Survodutide Earns Breakthrough Designation for MASH Treatment in China

Fineline Cube Jun 13, 2024

Boehringer Ingelheim (BI), the German pharmaceutical colossus, has declared that it has been granted Breakthrough...

Company Drug

Innovent Biologics’ CLDN18.2-Targeted ADC IBI343 Earns FDA Fast-Track Status

Fineline Cube Jun 13, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Drug

Zelgen Biopharmaceuticals’ Jacktinib Meets Primary Endpoint in Severe Alopecia Areata Trial

Fineline Cube Jun 13, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Drug

Joincare Pharmaceutical Receives NMPA Approval for Generic Seretide

Fineline Cube Jun 13, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a leading pharmaceutical company based in China,...

Policy / Regulatory

WuXi AppTec and WuXi Bio Shares Rally as US Biosecure Act Excluded from Defense Bill

Fineline Cube Jun 13, 2024

Shares of Chinese Contract Development and Manufacturing Organizations (CDMOs) WuXi AppTec (SHA: 603259) and WuXi...

Company

Haisco Pharmaceutical’s BRAF Inhibitor HSK42360 Gains NMPA Approval for Clinical Trials

Fineline Cube Jun 13, 2024

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a leading pharmaceutical company based in China, has...

Company Medical Device

Accuray Wins Chinese Nod for Precision Treatment Planning System, Boosting Regional Expansion

Fineline Cube Jun 13, 2024

U.S. medical device company Accuray Inc. (NASDAQ: ARAY) has announced that it has received market...

Company Deals

Pfizer Forges Partnership with Flagship Pioneering for Novel Obesity Treatments

Fineline Cube Jun 13, 2024

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has initiated a strategic partnership with Flagship Pioneering, a...

Posts pagination

1 … 340 341 342 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.